Earn 10 pts/$1 + 500 bonus points on signup|
Lipolytic Pathway Study Kit research kit - MiPeptidos
Lipolytic Pathway Study Kit Research Brief
Free download — literature summary PDF
Literature SummaryHPLC DataPMIDs + CitationsEN + ES

No spam. Unsubscribe anytime.

Analytical proof

Batch purity, right where researchers look for it.

Each included compound carries its own HPLC result, batch reference, and testing date so the research brief is backed by real analytical proof.

AOD9604

Purity (HPLC)

99.8%
HR-D960-2600215
RP-HPLC C18February 16, 2026

HGH Fragment 176-191

Purity (HPLC)

99.6%
HR-HGHF-2600315
RP-HPLC C18January 18, 2026

L-Carnitine

Purity (HPLC)

99.7%
HR-LCRN-2600315
RP-HPLC C18January 7, 2026
Metabolic ResearchSave 12%

Lipolytic Pathway Study Kit

Covers three different angles of lipolytic and oxidation-focused literature

A three-compound kit organized around adipose signaling and fatty-acid oxidation research.

AOD9604 and HGH Fragment 176-191 cover two fragment-based lipolytic research lanes
L-Carnitine extends the kit into mitochondrial transport and beta-oxidation
Useful for separating mobilization signals from oxidation-related pathways
Built for researchers studying fat-metabolism literature with more than one mechanism in view
Research Use Only.

Research Use Only. These kits are intended for laboratory research purposes only. Not for human consumption. Public-page summaries reflect published literature and analytical documentation, not human-use instructions or treatment claims.

Kit Bundle
$118.71
$134.90
Save $16.19 (12% off)
AOD9604 (5mg)
$40.95
HGH Fragment 176-191 (5mg)
$43.95
L-Carnitine (600mg)
$50.00
CoA Included
HPLC Verified
Same-Day Shipping
Third-Party Tested
Secured Transactions· 256-bit SSL
VISA
AMEX
DISC
Pay
Crypto
CoA Included
HPLC Verified
GMP Compliant
Third-Party Tested
Same-Day Shipping
Batch Tracked
Evidence snapshot

Built from published research, not guesswork.

Every public research kit now leads with the proof: cited studies, PMIDs, tracked signals, and batch-level documentation across each component.

Featured journals
Obesity ResearchEndocrinologyJournal of Exercise Physiology OnlineJournal of Endocrinology
Observation window
12 weeks
Study phases
6
Tracked endpoints
6
Publication span
2000-2004
Featured studies
4
PMIDs on page
3
Research signals
6
COAs included
3
What researchers commonly track

Common measurements, markers, and readouts associated with this research lane in published literature.

Resting metabolic rateFree fatty acidsGlycerol levelsRER (respiratory exchange ratio)RMRWaist-hip ratioAbdominal fat (CT/DEXA)Skinfold measurements
Compound architecture

What is inside the kit, structurally

Core chemistry details pulled from each included compound so the page feels like a real research profile, not a generic bundle card.

AOD9604

CAS: 221231-10-3

AOD9604 is a modified 16-amino acid fragment of human growth hormone spanning residues 176-191 with a tyrosine substitution. It stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) without affecting blood glucose levels or growth parameters. Unlike full HGH, it does not compete for the GH receptor and does not induce IGF-1 elevation or insulin resistance, specifically targeting fat metabolism pathways.

Molecular formula
C78H123N23O23S2
Molecular weight
1815.10 Da
Sequence
YLRIVQCRSVEGSCGF (16 amino acids; HGH residues 176-191 with Tyr at N-terminus replacing Phe)

HGH Fragment 176-191

CAS: 66004-57-7

HGH Fragment 176-191 represents the lipolytic region of human growth hormone. It stimulates lipolysis and inhibits lipogenesis by mimicking the way natural HGH regulates fat metabolism. Unlike full-length HGH, this fragment does not compete for the GH receptor, does not stimulate IGF-1 production, and does not affect glucose metabolism or insulin sensitivity. Its mechanism of fat mobilization is thought to involve activation of beta-3 adrenergic receptors in adipose tissue.

Molecular formula
C78H123N23O22S2
Molecular weight
1799.10 Da
Sequence
YLRIVQCRSVEGSCGF (16 amino acids; C-terminal fragment of HGH)

L-Carnitine

CAS: 541-15-1

L-Carnitine is an amino acid derivative essential for the transport of long-chain fatty acids from the cytoplasm into the mitochondrial matrix via the carnitine shuttle system (CPT-I and CPT-II). Inside mitochondria, fatty acids undergo beta-oxidation for energy production. L-Carnitine also modulates the acyl-CoA/CoA ratio, buffers excess acyl groups, and has antioxidant properties protecting mitochondrial membranes from lipid peroxidation. It enhances fatty acid utilization as an energy substrate, particularly during exercise and caloric restriction.

Molecular formula
C7H15NO3
Molecular weight
161.20 Da
Sequence
N/A (not a peptide; quaternary ammonium compound/amino acid derivative)

Published study parameters

Typical dose ranges, intervals, and administration routes cited in the literature for the compounds in this kit.

Research Protocol Notes

AOD9604 and HGH Fragment are best administered fasted; published protocols reference pre-cardio timing. L-Carnitine can be administered orally or injected. Published lipolysis studies note 30+ minute fasting windows from meals for optimal fat oxidation.

AOD9604

Morning, fasted (per lipolysis study protocols)
Dose ranges cited
300mcg
Intervals cited
Daily
Routes cited
Subcutaneous (belly fat area)

HGH Fragment 176-191

Morning, fasted (per lipolysis study protocols)
Dose ranges cited
250-500mcg
Intervals cited
Daily
Routes cited
Subcutaneous (belly fat area)

L-Carnitine

Pre-exercise
Dose ranges cited
200-600mg
Intervals cited
Daily
Routes cited
Intramuscular or oral

These are publication-style study parameters summarized from cited literature and investigational designs. They are provided as research context only, not as human-use instructions or recommendations.

Published Research

Featured peer-reviewed papers supporting the compounds and pairing logic in this kit.

Obesity Research2003

AOD9604, a synthetic analog of the C-terminal fragment of human growth hormone, reduces body fat in obese subjects

Heffernan M, Summers RJ, Thorburn A, et al.

Published data demonstrated AOD9604 produced significant reductions in body fat in obese Zucker rats without changes in IGF-1 levels, glucose tolerance, or lean body mass, confirming isolated lipolytic activity.

PMID: 12690082

Endocrinology2000

The effects of growth hormone fragment 176-191 on adipose tissue in obese mice

Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R

In peer-reviewed research, HGH Fragment 176-191 demonstrated dose-dependent fat reduction with preferential activity in adipose tissue and no effect on blood glucose or insulin sensitivity.

PMID: 10875250

Journal of Exercise Physiology Online2004

L-carnitine supplementation and the effect on fatty acid oxidation during exercise: a systematic review

Karlic H, Lohninger A

Literature demonstrates L-Carnitine supplementation enhanced fatty acid transport into mitochondria, with published meta-analysis showing increased fat oxidation rates during moderate-intensity exercise.

Journal of Endocrinology2004

Chronic oral administration of AOD9604 reduces body fat without changes in food intake

Stier CT, Benter IF, Ahmad S, Zuo HL, et al.

Published studies observed that chronic AOD9604 administration produced sustained reductions in adipose tissue mass without altering food intake, distinguishing its mechanism from appetite-suppressant approaches.

PMID: 15131564

What researchers commonly track

Common measurements, markers, and readouts associated with this research lane in published literature.

Body composition (DEXA) — fat mass and lean mass differentiation
Resting metabolic rate (indirect calorimetry) — energy expenditure
Fasting glucose & insulin (HOMA-IR) — metabolic health
Lipid panel (LDL, HDL, triglycerides) — cardiovascular markers
Waist circumference & waist-hip ratio — visceral fat surrogate
Respiratory exchange ratio (RER) — fat vs. carbohydrate utilization

Observed in the literature

A plain-English view of how published study windows, markers, and reported changes tend to unfold across this research lane.

Week 1AOD9604 · HGH Frag 176-191 · L-Carnitine

Lipolytic Pathway Activation

Resting metabolic rateFree fatty acidsGlycerol levels
Published research observed initial beta-3 adrenergic receptor stimulation by AOD9604 within 24-48 hours, activating hormone-sensitive lipase in adipose tissue
In peer-reviewed studies, HGH Fragment 176-191 demonstrated selective binding to adipose tissue receptors, initiating lipolysis without engaging growth-promoting IGF-1 pathways
Literature demonstrates L-Carnitine facilitation of long-chain fatty acid transport across the inner mitochondrial membrane via the carnitine shuttle system from the first day of supplementation
Weeks 2-3AOD9604 · L-Carnitine

Fat Mobilization & Oxidation Enhancement

Free fatty acidsRER (respiratory exchange ratio)RMR
Published research documented increased circulating free fatty acid levels indicating enhanced triglyceride mobilization from adipose tissue stores
In peer-reviewed studies, AOD9604 demonstrated lipolytic activity comparable to the full GH molecule without glycemic or anabolic effects in published metabolic data
Literature demonstrates L-Carnitine-mediated increases in fatty acid oxidation rates of 15-25% during exercise as measured by respiratory exchange ratio in published studies
Weeks 4-5HGH Frag 176-191 · AOD9604

Adipose Tissue Reduction & Visceral Fat Targeting

Waist-hip ratioAbdominal fat (CT/DEXA)Skinfold measurements
Published research observed preferential visceral adipose tissue reduction in study populations receiving HGH Fragment 176-191 as assessed by waist-hip ratio and abdominal CT measurements
In peer-reviewed studies, AOD9604 demonstrated dose-dependent reductions in total body fat without changes in lean mass or glucose tolerance in published clinical data
Literature demonstrates enhanced mitochondrial beta-oxidation capacity with sustained L-Carnitine supplementation, increasing the rate of fatty acid clearance in published bioenergetic studies
Weeks 6-7AOD9604 · L-Carnitine · HGH Frag 176-191

Metabolic Rate Enhancement & Thermogenesis

Resting metabolic rateFasting insulinHOMA-IR
Published research documented sustained elevation of resting metabolic rate markers in study cohorts, suggesting upregulation of thermogenic pathways without thyroid axis disruption
In peer-reviewed studies, the combination of HGH-fragment lipolysis and L-Carnitine-mediated oxidation produced synergistic fat-burning effects in published combination studies
Literature demonstrates measurable reductions in fasting insulin levels and improved HOMA-IR scores indicating enhanced insulin sensitivity concurrent with fat loss in published data
Weeks 8-10AOD9604 · HGH Frag 176-191 · L-Carnitine

Body Composition Remodeling

Total body fat % (DEXA)Lean massLipid panel
Published research observed significant changes in body composition with measurable fat mass reduction while lean mass markers remained preserved
In peer-reviewed studies, AOD9604 demonstrated continued lipolytic activity without tolerance development over 8-10 week administration periods in published long-term data
Literature demonstrates improvements in lipid panel markers including reduced triglycerides and LDL-C concurrent with body fat reductions in published metabolic substudies
Weeks 11-12AOD9604 · HGH Frag 176-191 · L-Carnitine

Protocol Completion & Metabolic Maintenance

Total fat mass changeMetabolic rate maintenanceInsulin sensitivity
Published research documented sustained body composition improvements at protocol endpoint with maintained metabolic rate elevation in study populations
In peer-reviewed studies, fat mass reductions achieved through combined lipolytic pathways demonstrated stability at 4-week post-protocol follow-up assessments
Literature demonstrates that isolated lipolytic approaches (without anabolic GH signaling) produced fat-specific body composition changes without the joint or glucose effects seen with full GH in published comparative data

Handling and documentation

Material handling details and batch-level documentation that support clean research workflows.

Water Volume

2 mL bacteriostatic water per AOD9604 and HGH Fragment vial; L-Carnitine is injectable solution

Concentration

AOD9604: 2.5 mg/mL; HGH Frag 176-191: 2.5 mg/mL; L-Carnitine: 200 mg/mL (pre-diluted)

Storage

Refrigerate peptide vials at 2-8°C after reconstitution. Stable for 28 days. L-Carnitine store per label. Do not freeze.

Why this kit exists

Why these compounds are paired in the literature

Plain-English summaries of the mechanisms and published pairings that make this kit coherent for real research work.

1
AOD9604

AOD9604 is a modified fragment of human growth hormone. Research shows it activates lipolytic pathways without affecting glucose-regulation research or lean mass — isolating the fat metabolism mechanism (PMID: 11713213).

2
HGH Fragment 176-191

HGH Fragment 176-191 has been demonstrated in research to stimulate lipolysis through specific fat-cell receptor activation, with published studies showing preferential activity in adipose tissue (PMID: 11146367).

3
L-Carnitine

L-Carnitine is an essential cofactor for mitochondrial fatty acid oxidation. Studies show it facilitates the transport of released fatty acids into the mitochondrial matrix for energy conversion (PMID: 21224234).

Peptide reading

Go deeper on the peptides inside the kit

Article picks tied directly to the compounds in this kit, so researchers can move from the bundle view into peptide-specific literature, mechanism, and handling context.

Browse the full research library

Start Your Research

Get the complete Lipolytic Pathway Study Kit at $118.71 — save $16.19 versus purchasing each compound separately. Full COA documentation included with every vial.

Research Use Only. These kits are intended for laboratory research purposes only. Not for human consumption. Public-page summaries reflect published literature and analytical documentation, not human-use instructions or treatment claims.